Lead Product(s): Ciprofloxacin
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Otiprio
Highest Development Status: Approved Product Type: Small molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 17, 2020
Under the terms of the agreement, ALK will have exclusive rights to promote OTIPRIO for AOE to office-based healthcare professionals in the U.S. including ENT physicians, pediatricians and select primary care physicians.